Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURMOUNT-MMO: Tirzepatide for Reduction of Morbidity and Mortality in Adults With Obesity
NCT05556512Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2022
- Primary completion
- Oct 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 28
01
Overview
A Phase 3 trial of tirzepatide in obesity, sponsored by Eli Lilly and Company. Started Oct 2022; status: active, not recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05556512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05556512.